Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 2/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 11/20 | 0.53 |
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | FLT1 | P17948 | 4/20 | 0.51 |
| ▸ | FLT4 | P35916 | 4/20 | 0.51 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4169759 | 0.82 | VCP (0.53) | VCPIMPDH2KDRFLT1FLT4 | |
| SCHEMBL13605799 | 0.81 | VCP (0.60) | VCPIMPDH2KDRFLT1FLT4 | |
| SCHEMBL4188112 | 0.81 | KDR (0.56) | VCPIMPDH2KDRFLT1FLT4 | |
| SCHEMBL4173774 | 0.81 | HTR1A (0.54) | VCPIMPDH2KDRFLT1FLT4 | |
| Hydrochloric Acid SCHEMBL4181141 | 0.80 | VCP (0.58) | VCPIMPDH2KDRFLT1FLT4 | |
| SCHEMBL4181132 | 0.77 | MEN1 (0.60) | VCPIMPDH2KDRFLT1FLT4 | |
| SCHEMBL4175646 | 0.76 | KDR (0.54) | VCPIMPDH2KDRFLT1FLT4 | |
| SCHEMBL5477528 | 0.73 | VCP (0.80) | VCPIMPDH2KDRFLT1FLT4 | |
| SCHEMBL6182372 | 0.73 | VCP (0.46) | VCPIMPDH2KDRFLT1FLT4 | |
| SCHEMBL13612941 | 0.73 | VCP (0.50) | VCPIMPDH2KDRFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2005004818-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | VCP 1689/4885IMPDH2 1793/4885KDR 3284/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | VCP 1689/4885IMPDH2 1793/4885KDR 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.